elbasvir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals, hepatitis C Virus (HCV) NS5A inhibitors 5080 1370468-36-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • elbasvir
  • MK-8742
  • MK 8742
inhibits NS5A protein of hepatitis C virus
  • Molecular weight: 882.04
  • Formula: C49H55N9O7
  • CLOGP: 6.66
  • LIPINSKI: 3
  • HAC: 16
  • HDO: 4
  • TPSA: 188.80
  • ALOGS: -5.30
  • ROTB: 13

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 28, 2016 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fatigue 432.87 42.61 277 1633 608420 46075732
Headache 373.65 42.61 232 1678 478120 46206032
Nausea 151.02 42.61 160 1750 687294 45996858
Insomnia 92.19 42.61 66 1844 164858 46519294
Product dose omission issue 88.63 42.61 65 1845 168455 46515697
Hepatitis C 50.33 42.61 16 1894 6302 46677850
Pancreas transplant rejection 49.68 42.61 8 1902 137 46684015

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fatigue 591.38 44.17 331 1861 320342 29629944
Headache 382.77 44.17 207 1985 182099 29768187
Nausea 112.56 44.17 122 2070 296835 29653451
Insomnia 91.34 44.17 66 2126 93270 29857016
Product dose omission issue 83.31 44.17 62 2130 91569 29858717
Hepatitis C 81.19 44.17 32 2160 13173 29937113
Treatment failure 57.00 44.17 34 2158 34645 29915641

Pharmacologic Action:

SourceCodeDescription
ATC J05AP10 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
ATC J05AP54 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
FDA EPC N0000191256 Hepatitis C Virus NS5A Inhibitor
CHEBI has role CHEBI:36044 anti-virus drug
CHEBI has role CHEBI:62868 antihepatotoxic agent
CHEBI has role CHEBI:85185 ns5a inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic hepatitis C indication 128302006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.46 acidic
pKa2 12.98 acidic
pKa3 13.06 acidic
pKa4 13.59 acidic
pKa5 5.64 Basic
pKa6 5.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
50MG;100MG ZEPATIER MERCK SHARP DOHME N208261 Jan. 28, 2016 RX TABLET ORAL Jan. 28, 2021 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Genome polyprotein Polyprotein INHIBITOR EC50 11.40 DRUG LABEL DRUG LABEL
Genome polyprotein Polyprotein INHIBITOR EC50 11.52 DRUG LABEL DRUG LABEL
Genome polyprotein Polyprotein INHIBITOR EC50 12.52 DRUG LABEL DRUG LABEL

External reference:

IDSource
D10625 KEGG_DRUG
4035373 VANDF
C4080052 UMLSCUI
CHEBI:132967 CHEBI
CHEMBL3039514 ChEMBL_ID
DB11574 DRUGBANK_ID
C000589335 MESH_SUPPLEMENTAL_RECORD_UI
71661251 PUBCHEM_CID
9851 INN_ID
632L571YDK UNII
1734628 RXNORM
31482 MMSL
d08416 MMSL
016673 NDDF
716042006 SNOMEDCT_US
816100007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZEPATIER HUMAN PRESCRIPTION DRUG LABEL 2 0006-3074 TABLET, FILM COATED 50 mg ORAL NDA 31 sections